About: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) наукова стаття, опублікована в червні 1997 (uk) article scientifique publié en 1997 (fr) im Juni 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1997 (ast) scientific article published on 01 June 1997 (en)
publication date	wds:Q73443071-0429506B-BDD6-46F9-BA72-D21F2A09AD8E
publication date	1997-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73443071-B2E65A81-C930-43C8-A79E-41A9F5AAC8DF
language of work or name	English
author name string	wds:Q73443071-379DC2C2-27DB-4805-918E-D6D5D32AD3B4 wds:Q73443071-42925533-5BAB-4444-9C35-B61626A99C45 wds:Q73443071-574BCBAF-7260-476C-89E8-561D36DD7D24 wds:Q73443071-6CE2CEAC-6B30-4D60-829E-3E71448C54B8 wds:Q73443071-8430171A-ADD6-48FC-A182-59B19B4740C9 wds:Q73443071-875CA1C6-4EFF-4D13-BD17-7FAC11826716 wds:Q73443071-8BA58E3D-B646-4B55-BD57-55B3B068742A wds:Q73443071-96FB8BE1-7059-4DD3-9C9B-97DA38BAF009 wds:Q73443071-9CBB700A-B29A-4014-9D86-8E69D23225E7 wds:Q73443071-A531A88D-2F46-434B-B3E5-19DB2346A974 wds:Q73443071-C5B14A50-ABF4-4D7B-A1A8-15358DC119AE wds:Q73443071-C5DC815A-4C07-4DCA-93DA-D8B8AE02D95A wds:Q73443071-E0483564-DD54-4595-A120-89BA3AF283AD wds:Q73443071-EB66AB72-A183-4361-A66D-A5DEB5B24FD9 wds:Q73443071-FE44B0B1-1CCA-4EA3-953A-C3BAA4CC8086
author name string	A Gordon M Gore N Davidson J Carmichael I Hudson W ten Bokkel Huinink G Bolis R Coleman H Malmström C Broom J Malfetano C Scarabelli J F Heron M Spanczynski S C Fields
rdfs:label	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (en) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (nl)
skos:prefLabel	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (en) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (nl)
name	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (en) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (nl)
title	wds:Q73443071-FF473E51-4825-4C50-8AE9-36F84AFFE4DE
title	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (en)
page(s)	wds:Q73443071-3A996A4B-9FA4-47EF-A150-114EBD830178
page(s)	2183-2193
instance of	wds:Q73443071-9854ABA3-C336-4515-86CE-8DD03B33397C
instance of	scholarly article
main subject	wds:Q73443071-3EE5A50C-3CB3-487A-90EB-4A9C66225863 wds:Q73443071-9DB85F43-CA3B-40DD-A1BB-5D791C6F6298
main subject	ovarian neoplasm wd:Q423762
PubMed ID	wds:Q73443071-502E01EE-546C-4D43-9394-4F3DB731AB9E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9196130
PubMed ID	9196130
published in	wds:Q73443071-92C59A65-FE92-4E4D-AE96-4FA3C61B8FBE
published in	Journal of Clinical Oncology
issue	wds:Q73443071-F2B79072-493D-461C-9360-68CC6DA236D0
volume	wds:Q73443071-17D208AF-8D01-4D38-B5F1-259ECACE9853
issue	6
volume	15
DOI	wds:Q73443071-CF761393-CD41-4833-BFB8-4029C001C9CC
DOI	http://dx.doi.org/10.1200/JCO.1997.15.6.2183
DOI	10.1200/JCO.1997.15.6.2183
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73443071
is cites work of	The taxanes: an update A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group Phase II study of gemcitabine in ovarian cancer Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas Mechanisms of resistance to topoisomerase I-targeting drugs Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Topoisomerase I inhibitors: review and update Camptothecins: a review of their development and schedules of administration Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin Latest research and treatment of advanced-stage epithelial ovarian cancer Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan The role of plant-derived drugs and herbal medicines in healthcare Pharmaceutical management of ovarian cancer : current status Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software